Journal Mobile Options
Table of Contents
Vol. 24, No. 1, 2007
Issue release date: June 2007
Dement Geriatr Cogn Disord 2007;24:36–41
(DOI:10.1159/000102570)

A Placebo-Controlled Double-Blind Randomized Study of Venlafaxine in the Treatment of Depression in Dementia

de Vasconcelos Cunha U.G. · Lopes Rocha F. · Ávila de Melo R. · Alves Valle E. · de Souza Neto J.J. · Mendes Brega R. · Magalhães Scoralick F. · Araújo Silva S. · Martins de Oliveira F. · da Costa Júnior A.L. · Xavier Faria Alves V. · Sakurai E.
aGeriatric Unit and bPsychiatric Unit, Governador Israel Pinheiro Hospital, and cStatistical Department, Federal University, Minas Gerais, Brazil

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background/Aims: To evaluate the efficacy and safety of venlafaxine in the treatment of major depression in dementia. Methods: Thirty-one outpatients who had dementia and major depression participated in this randomized, double-blind, placebo-controlled, 6-week, flexible dose clinical trial. The screening measures were Cornell Scale for depression in dementia, DSM-IV for depression and dementia and Mini-Mental State Examination. The outcome measures were response rate, Montgomery-Åsberg Depression Rating scale and Clinical Global Impressions. Results: The percentage of patients defined as Montgomery-Åsberg Depression Rating scale responders was approximately the same in the placebo and in the venlafaxine groups. Clinical Global Impressions showed no significant difference between the groups. The reasons for dropouts show borderline significance between the two groups. There was no statistically significant difference in the incidence of adverse events between the venlafaxine and placebo-treated groups. Conclusions: Our data do not support the hypothesis that venlafaxine improves mood in elderly demented patients.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Bouchard RW, Rossor MN: Typical clinical features; in Gauthier S (ed): Clinical Diagnosis and Management of Alzheimer’s Disease. London, Dunitz, 2001, pp 57–71.
  2. Baldwin RC, Anderson D, Black S, et al: Guideline for the management of late-life depression in primary care. Int J Geriatr Psychiatry 2003;18:829–838.
  3. Beekman AT, Copeland JR, Prince MJ: Review of community prevalence of depression in later life. Br J Psychiatry 1999;174:307–311.
  4. Lebowitz BD, Pearson JI, Schneider LS, et al: Diagnosis and treatment of depression in later life. JAMA 1997;278:1186–1190.
  5. Ballard C, Bannister C, Solis M, Oyebode F, Wilcock G: The prevalence, association and symptoms of depression amongst dementia sufferers. J Affect Disord 1996;36:136–144.

    External Resources

  6. Burns A, Jacoby R, Levy R: Psychiatric phenomena in Alzheimer disease. III. Disorders of mood. Br J Psychiatry 1990;157:81–86.
  7. Gonzales-Salvador T, Lyketsos CG, Baker AS, Roques C, Hovanec L, Steele CD, Brandt J: Quality of life of patients with dementia in long-term care. Int J Geriatr Psychiatry 2000;15:181–189.
  8. Lyketsos CG, Baker L, Warren A, Steele C, Brant J, Steinberg M, Kopunek S, Baker A: Major and minor depression in Alzheimer’s disease: prevalence and impact. J Neuropsychiatry Clin Neurosci 1997;9:556–561.
  9. Steele C, Rovner B, Chase GA, Folstein M: Psychiatric symptoms and nursing home placement of patients with Alzheimer’s disease. Am J Psychiatry 1990;147:1049–1051.
  10. Gonzalez–Salvador T, Aragano C, Lyketsos CG, Barba AC: The stress and psychological morbidity of the Alzheimer patient caregiver. Int J Geriatr Psychiatry 1999;14:701–710.
  11. Hoch CC, Reynolds CF, Buysse DJ: Two-year survival in patients with mixed symptoms of depression and cognitive impairment: comparison with major depression and primary degenerative dementia. Am J Geriatr Psychiatry 1993;1:59–66.

    External Resources

  12. Reifler BV, Teri L, Raskind M, et al: Double-blind trial of imipramine in Alzheimer’s disease patients with and without depression. Am J Psychiatry 1989;146:45–49.
  13. Petracca GM, Chemerimski E, Starkstein SE: A double blind, placebo controlled study of fluoxetine in depressed patients with Alzheimer’s disease. Int Psychogeriatr 2001;3:233–240.

    External Resources

  14. Magai C, Kennedy G, Cohen CL, Gomberg D: A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer’s disease. Am J Geriatr Psychiatry 2000;8:66–74.
  15. Lyketsos CG, Sheppard JM, Steele CD, et al: Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer’s disease: initial results from the depression in Alzheimer’s disease study. Am J Psychiatry 2000;157:1686–1689.
  16. Lyketsos CG, DelCampo L, Steinberg M, Miles Q, Steele CD, Munro C, Baker AS, Sheppard JM, Frangakis C, Brandt J, Rabins PV: Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction – the DIADS. Arch Gen Psychiatry 2003;60:737–746.
  17. Nyth AL, Gottfries CG, Lyby K, et al: A controlled multicenter study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 1992;86:138–145.
  18. Roth M, Mountjoy CQ, Amrein R: Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. Br J Psychiatry 1996;168:149–157.
  19. Petracca G, Teson A, Chemerinski E, et al: A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 1996;8:270–275.
  20. Amore M, Ricci M, Zanardi R, Perez J, Ferrari G: Long-term treatment of geropsychiatric depressed patients with venlafaxine. J Affect Disord 1997;46:293–296.
  21. Cervera-Enguix S, Baca-Baldomero E, Garcia-Calvo C, Prieto-Lopez R; TESEO Study Group: Depression in primary care: effectiveness of venlafaxine extended-release in elderly patients – observational study. Arch Gerontol Geriatr 2004;3:271–280.

    External Resources

  22. Dierick M: An open-label evaluation of the long-term safety of oral venlafaxine in depressed elderly patients. Ann Clin Psychiatry 1996;11:169–178.

    External Resources

  23. Mahapatra SN, Hackett D: A randomised, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patients with major depression. Int J Clin Pract 1997;51:209–213.
  24. Allard P, Gram L, Timdahl K, Behnke K, Hanson M, Sogaard J: Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram. Int J Geriatr Psychiatry 2004;19:1123–1130.
  25. Gasto C, Navarro V, Marcos T, Portella MJ, Torra M, Rodamilans M: Single-blind comparison of venlafaxine and nortriptyline in elderly major depression. J Clin Psychopharmacol 2003;23:21–26.
  26. Klamerus KJ, Parker VD, Rudolph RL, Derivan AT, Chiang ST: Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Pharmacotherapy 1996;16:915–923.
  27. Khan A, Rudolph R, Baumel B, Ferguson J, Ryan P, Shrivastava R: Venlafaxine in depressed geriatric outpatients: an open-label clinical study. Psychopharmacol Bull 1995;31:753-758.
  28. Owens JR, Nemeroff CB: New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone and mirtazapine. Depress Anxiety 1998;7(suppl 1):24–32.

    External Resources

  29. Hansen RA, Gartiehner G, Lohr KN, Gaynes BN, Carey TS: Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005;143:415–426.
  30. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR, ed 4, rev. Washington, American Psychiatric Association, 2000.
  31. Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 1975;12:189–198.
  32. Alexopoulous GS, Abrams RC, Young RC, et al: Cornell Scale for Depression in Dementia. Biol Psychiatry 1998;23:271–284.

    External Resources

  33. Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382–389.
  34. Guy W: ECDEU Assessment Manual for Psychopharmacology (publication 76-338). Washington, US Department of Health, Education and Welfare, 1976.
  35. Rockwell E, Lam RW, Zisook S: Antidepressant drug studies in the elderly. Psychiatr Clin North Am 1988;11:26–30.
  36. Cunningham LA; Venlafaxine XR 208 Study Group: Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Ann Clin Psychiatry 1997,9:157–164.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50